• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

kphi@unimelb.edu.au

Credentials


Position
Honorary (Professorial Fellow)
The Sir Peter MacCallum Department of Oncology
Education
Doctorate
Monash University
Bachelors Degree (Honours)
Monash University
ORCID

0000-0002-0475-1771

Prof Kelly Phillips

Honorary (Professorial Fellow)
The Sir Peter MacCallum Department of Oncology

348 Scholarly works
30 Projects

HIGHLIGHTS

  • 2026

    Research grants (ARC, NHMRC, MRFF)

    Precision Prevention, Targeted Treatment and Improved Survivorship to Decrease the Burden of Breast Cancer
  • 2024

    Journal article

    BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
    DOI: 10.1186/s12943-024-02048-1
  • 2022

    Journal article

    Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice.
    DOI: 10.1038/s43018-022-00413-x
  • 2021

    Journal article

    Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation.
    DOI: 10.1093/jnci/djab111
  • 2021

    Journal article

    Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians.
    DOI: 10.1158/1940-6207.capr-20-0369
  • 2021

    Research grants (ARC, NHMRC, MRFF)

    Reducing the Burden of Breast Cancer Through Precision Prevention, Targeted Treatment and Enhanced Survivorship
  • 2021

    Research Grant

    A New Way to Deliver Breast Cancer Prevention
Kelly Phillips

Latest Honours,
Awards and Fellowships


2018
FAHMS - Fellow of the Australian Academy of Health and Medical Sciences
2017
Practitioner Fellowship National Breast Cancer Foundation
2016
Excellence in Cancer Prevention and Wellbeing Peter MacCallum Cancer Centre
2015
Annual Scientific Meeting, Best Oral Presentation in Epidemiology Clinical Oncology Society of Australia (COSA)

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Risks of non-breast, non-ovarian cancers for BRCA1 and BRCA2 pathogenic variant carriers: a prospective cohort study
    DOI: 10.1186/s12916-026-04753-8
  • 2026

    Journal article

    Radiation therapy management in BRCA1/2 carriers diagnosed with early breast cancer: An international cohort study
    DOI: 10.1016/j.radonc.2026.111523
  • 2026

    Journal article

    Unlocking the Potential of Risk-Based Screening for Breast Cancer: From Detection to Prevention
    DOI: 10.1001/jama.2025.24817
  • 2026

    Journal article

    Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study
    DOI: 10.1016/j.annonc.2025.11.004
  • 2026

    Journal article

    Abstract RF5-03: OlympiaN: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with BRCA mutations and early-stage HER2-negative breast cancer
    DOI: 10.1158/1557-3265.sabcs25-rf5-03
  • 2026

    Journal article

    Abstract PD7-11: Impact of neoadjuvant pembrolizumab on ovarian function in young patients with triple-negative breast cancer (TNBC): Longitudinal analysis from NeoSTOP and NeoPACT trials
    DOI: 10.1158/1557-3265.sabcs25-pd7-11
  • 2026

    Journal article

    Parity and lactation induce T-cell-mediated breast cancer protection
    DOI: 10.1038/s41586-025-09713-5
  • 2025

    Journal article

    Breastfeeding after breast cancer in young BRCA carriers
    DOI: 10.1093/jnci/djaf177

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224